Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: A report of two cases

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1166-1168

  Frikha, Faten ^a   Rigolet, Aude ^a   Behin, Anthony ^a   Fautrel, Bruno ^a   Herson, Serge ^a   Benveniste, Olivier ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; IMMUNOGLOBULIN; JO 1 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; AUTOANTIBODY; HISTIDINE TRANSFER RNA LIGASE; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; CASE REPORT; CLINICAL FEATURE; DELTOID MUSCLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LEG MUSCLE; LETTER; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; PRIORITY JOURNAL; PSOAS MUSCLE; RELAPSE; SUPINE POSITION; TREATMENT OUTCOME; TREATMENT RESPONSE; AUTOIMMUNE DISEASE; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HISTIDINE-TRNA LIGASE; HUMANS; MIDDLE AGED; MYOSITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349786727     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep147     Document Type: Letter

References (10)

1. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-5.
2. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
3. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
4. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26:887-93.
5. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, Ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. Advance Access published February 1, 2009, doi: 10.1007/s00296- 009-0859-x.
6. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007;46:626-30.
7. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
8. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
9. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7.
10. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-8.